Angela Thedinga
Director/Board Member bij NKARTA, INC.
Vermogen: - $ op 31-03-2024
Profiel
Angela M.
Thedinga is an Independent Director at Nkarta, Inc. She was previously the Chief Technology Officer at Adverum Biotechnologies, Inc. from 2020 to 2021 and the Chief of Staff & VP-Program Management at Novartis Gene Therapies, Inc. from 2018 to 2019.
Ms. Thedinga has a graduate degree from Massachusetts Institute of Technology, an undergraduate degree from the University of Wisconsin, a graduate degree from The University of North Carolina at Chapel Hill, and an MBA from MIT Sloan School of Management.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
NKARTA, INC.
-.--% | 14-04-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Angela Thedinga
| Bedrijven | Functie | Begin |
|---|---|---|
| NKARTA, INC. | Director/Board Member | 28-03-2022 |
Eerdere bekende functies van Angela Thedinga
| Bedrijven | Functie | Einde |
|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Chief Tech/Sci/R&D Officer | 01-10-2021 |
| AVEXIS INC | Human Resources Officer | 01-06-2019 |
Opleiding van Angela Thedinga
| Massachusetts Institute of Technology | Graduate Degree |
| University of Wisconsin | Undergraduate Degree |
| The University of North Carolina at Chapel Hill | Graduate Degree |
| MIT Sloan School of Management | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| NKARTA, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
